Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017

Business Wire May 17, 2017

New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab)

Business Wire May 17, 2017

Technical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma

PR Newswire May 11, 2017

Investor Network: Incyte Corporation to Host Earnings Call

Accesswire May 4, 2017

Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs

Business Wire May 4, 2017

CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments

GlobeNewswire May 3, 2017

Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.

PR Newswire April 28, 2017

Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments

GlobeNewswire April 28, 2017

Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Benzinga.com  April 25, 2017

Incyte to Present at Upcoming Investor Conferences

Business Wire April 25, 2017

Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow

Benzinga.com  April 24, 2017

Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting

Business Wire April 20, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)

PR Newswire April 20, 2017

Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher

Benzinga.com  April 17, 2017

Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide

Benzinga.com  April 17, 2017

The Market In 5 Minutes

Benzinga.com  April 17, 2017

U.S. FDA Issues Complete Response Letter for Baricitinib

Business Wire April 14, 2017

Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials

Business Wire April 2, 2017

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)

Business Wire March 31, 2017

Gilead Looking To Buy Incyte? It Makes Sense

Benzinga.com  March 14, 2017